Search Results for: 119

Theriva™ Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

February 16, 2023 12:05 ET – Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR – – Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with HCT and was not observed in blood samples from the majority of the evaluable patients – ROCKVILLE, Md., Feb. 16, […]

Theriva™ Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Read More »

Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

IRB Approval Signals Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients May Proceed as Planned; Enrollment Anticipated to Commence During Q1 2021 ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet

Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol Read More »

Synthetic Biologics Receives USAN Approval for Generic Name Ribaxamase for Phase 2 Drug Candidate SYN-004

— Ribaxamase Designed for the Prevention of C. difficile Infection, Antibiotic-Associated Diarrhea & the Emergence of Antibiotic-Resistant Organisms — — Oral Presentation Planned for ANAEROBE 2016 — ROCKVILLE, Md., July 7, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific

Synthetic Biologics Receives USAN Approval for Generic Name Ribaxamase for Phase 2 Drug Candidate SYN-004 Read More »

Synthetic Biologics Reports Third Quarter 2015 Financial Results and Operational Highlights

— Initiated Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection and Antibiotic Associated Diarrhea — — Initiated Second Phase 2 Clinical Trial to Evaluate the Sustainability of Reduced Methane Production in Patients with Irritable Bowel Syndrome with Constipation — — Conference Call Today, November 5, 2015, at 4:30 p.m. EST —

Synthetic Biologics Reports Third Quarter 2015 Financial Results and Operational Highlights Read More »

Synthetic Biologics to Report Third Quarter Results on November 5, 2015

— Conference Call Scheduled for Thursday, November 5, 2015 at 4:30 p.m. EST — ROCKVILLE, Md., Oct. 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and nine months ended September

Synthetic Biologics to Report Third Quarter Results on November 5, 2015 Read More »

Synthetic Biologics to Report Second Quarter Results on August 10, 2015

— Conference Call Scheduled for Monday, August 10, 2015 at 8:30 a.m. EDT — ROCKVILLE, Md., July 29, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and six months ended June

Synthetic Biologics to Report Second Quarter Results on August 10, 2015 Read More »